Ozette in the news.

Read all about what we’ve been up to in our latest news and recent publications.

BioTech Breakthrough Recognizes Ozette as the 2022 Overall Immunology Company of the Year

November, 2022

We’re honored to be named the 2022 Overall Immunology Company of the Year by BioTech Breakthrough. Ozette’s computational immune profiling tech breaks through complex, highly dimensional datasets to revolutionize our understanding of the human immune system. BioTech Breakthrough recognizes Ozette for accelerating scientific collaboration with automated and interpretable single-cell analysis at unprecedented speed, dimensionality, and annotation depth to capture the full value of single-cell immune data.

Ozette named one of the 21 most promising healthtech startups of 2022.

July 19, 2022

Business Insider features Ozette as one of the 21 most promising healthtech startups, along with Solv, Truepill and WELL Health, as ranked by VCs. Haomiao Huang at Kleiner Perkins nominated Ozette, noting that, “Ozette’s AI-driven solution has been succeeding in turning these high-dimensional problems in immune profiling into solvable and usable building blocks for drug development and scientific research.” Click through to Business Insider to read the full list, available with subscription.

Ozette announces $26MM in series A Funding

July 28, 2022

Ozette, a technology-driven life sciences startup engineering a transformative leap in cell discovery and annotation of the human immune system, today announced its $26MM Series A funding, led by Madrona Ventures. Other participating investors include Cercano Management (formerly Vulcan Capital), M12, Microsoft’s venture fund, Alexandria Venture Investments, OCV Partners and Duke University.

CZI announces project with Ozette Co-Founder

July 19, 2022

We’re proud to announce Ozette co-founder and Scientific Advisor Dr. Raphael Gotardo’s role as principal investigator for The Chan Zuckerberg Initiative project to decode single-cell CITE-seq data, co-led by associate professor at the Fred Hutchinson Cancer Center Dr. Evan Newell. 

AI for immune data

August 18, 2021

Hear Ozette co-founder and CTO Greg Finak discuss how we leverage machine learning in next generation high-resolution immune profiling.

Ozette raises 6M seed

February 16, 2021

Fred Hutch spin out Ozette, raises 6M in seed funding to develop its AI powered immune monitoring platform in a round led by Madrona Venture Group. Ozette’s raise will fund team growth and technology development.

Case-studies & more

An incomplete list of Ozette news and featured publications.

Case Study

Going beneath the
surface of skin cancer.

We investigated our AI’s ability to predict treatment response to PD1 inhibiting immunotherapy in Merkel cell carcinoma and melanoma. We benchmarked our algorithmic approach against conventional analysis.

Case Study

Ozette’s AI in the battle
against COVID-19.

In-depth immune profiling reveals a T regulatory signature that correlates with COVID-19 disease severity, an important finding as Treg cells are potential targets for treatment strategies and fighting severe disease.

Case Study

Ozette’s AI aids advancement of cancer drug development.

Ozette’s technology, in conjunction with other new methods, reveal a distinct T cell population that suppresses immune effectiveness in the tumor microenvironment and helps inform drug development in immuno-oncology.

Ozette partners with Fred Hutch's CITN

Feb 14, 2022

Fred Hutch’s Cancer Immunotherapy Trials Network (CITN) has pioneered cancer immunotherapy trials which leverage immune profiling. In a unique collaboration, the CITN has tapped Ozette to analyze data from completed and ongoing early-phase clinical trials to provide unique insights on novel leads.